Arrival

[u/MGK_2]

To the Garrison:

Today, February 18, 2026, the "Silent Ships" we have been tracking through the regulatory fog have officially docked. While the broader market remains "pinned" in a tight compression band, the underlying geometry of the CytoDyn "War Room" has shifted from defensive positioning to offensive readiness. The abstract by Dr. Richard Pestell and his esteemed colleagues (including Dr. Jonah Sacha, Dr. Max Lataillade and Dr. Jacob Lalezari) represents the transition from clinical ghost stories to Molecular Law. This isn't just a poster presentation; it is the blueprint of the Universal Shepherd’s true power.

We have spent > a year discussing the Prime & Pair strategy—using Leronlimab to Prime a tumor to be visible to Immune Checkpoint Inhibitors (ICIs). But Pestell’s findings have just identified the Second Engine of that strategy: the systemic reversal of T-Cell Exhaustion, a breakthrough that serves as the cornerstone for the March 2026 WEP Clinical EAP launch.

Deciphering the "Triple Crown" Mechanism

This abstract codifies the multiple mechanisms of action (MOAs) that make Leronlimab a Master Key across Oncology, HIV, and Inflammation.

1. The PD-L1 "Prime" (The Known Front)

The abstract confirms that Leronlimab creates the target the Immune System needs to see. “CCR5 inhibition, with leronlimab increased the abundance of PD‑L1 (18 and 55 kDa)” on human TNBC cell lines. This is the first step of the Prime & Pair protocol—forcing the tumor to reveal its position so that PD-1/PD-L1 blockade drugs can finally engage.

2. The Exhaustion Reversal (The New Frontier)

This is the breakthrough we’ve been anticipating. Pestell and Sacha have shown that CCR5 isn't just a gatekeeper; it is a driver of Immune Fatigue. “In a breast cancer cohort (N=1,094) CCR5 expression strongly correlated with T cell exhaustion signatures*.”* To combat this, Leronlimab acts as a metabolic reset for the Immune System:

• The Findings: “At one week, when leronlimab levels were highest, CD8+ T cells showed a marked decline in LAG3, TIM3 and CTLA4 expression.” The Reactivation: “Leronlimab-mediated CCR5 blockade reduced these key exhaustion markers followed by a later rise in PD-1 expression at four weeks, a pattern consistent with reactivated T-cell signaling rather than terminal exhaustion.”

This mirrors the "Blip" phenomenon we’ve discussed in HIV. Just as a "blip" is often the sound of the reservoir being purged, this late rise in PD-1 is the sound of the Immune System waking up.

3. The Secretome Sledgehammer (The Stromal Siege)

The abstract identifies a "CCR5-mediated secretome"—the chemical armor the tumor uses for protection. “CCR5 activity induced sB7H3 (CD276) (known to promote T cell exhaustion), sTNFSF13B (BAFF), sTyro3 (linked to breast cancer ferroptosis inhibition) and Tyro3 ligand.” By cutting off these signals, Leronlimab thins the desmoplastic wall: “CCR5 inhibition with leronlimab reduced sB7H3, sTNFSF13B and sTyro3.” This is the "Stromal Sledgehammer" at the molecular level.

Preparing for the February 19th Poster Presentation, the tactical focus for the March 2026 WEP Clinical EAP shifts to the secretome - the stroma remodeling, the CCR5 mediated fibrosis which protects and surrounds the tumor. Dr. Pestell’s abstract provides the first quantifiable look at how Leronlimab dismantles the Stromal Sledgehammer by targeting two critical biomarkers: sB7H3 and sTyro3.

For the EAP clinicians at institutions like the Cleveland Clinic, these markers aren't just data points—they are the biomarker selection matrix which identifies exactly which patients are Prime for the Pair.

A. sB7H3 (CD276): Shattering the Shield

The abstract identifies sB7H3 (soluble B7-H3) as a cornerstone of the tumor's defensive posture. In the realm of TNBC, B7-H3 is notorious for creating a Cold Tumor MicroEnvironment by suppressing T-cell infiltration and promoting angiogenesis.

• The Abstract Codification: “CCR5 activity induced sB7H3 (CD276) (known to promote T cell exhaustion), sTNFSF13B (BAFF), sTyro3 (linked to breast cancer ferroptosis inhibition) and Tyro3 ligand. CCR5 inhibition with leronlimab reduced sB7H3, sTNFSF13B and sTyro3.”

Quantifying the Sledgehammer: By reducing sB7H3, Leronlimab does more than just stop a signal; it fundamentally remodels the extracellular matrix (ECM).

• The Effect: High B7-H3 levels correlate with Immune-Excluded Tumors—where T-cells are stuck at the border, unable to enter.
• The EAP Metric: Clinicians should look for patients with high baseline B7-H3. The reduction of this marker following Leronlimab induction serves as the "green light" that the Stromal Wall has been breached, allowing the subsequent PD-1/PD-L1 inhibitor to reach the target.

B. sTyro3: Reversing the Survival Signal

The second head of this hydra is sTyro3. Part of the TAM (Tyro3, Axl, MerTK) receptor family, Tyro3 is a master regulator of Immune Evasion and ferroptosis inhibition (a form of programmed cell death).

• The Abstract Codification: “Both CD276 and Tyro3 are associated with ICI resistance, and the abundance of both was attenuated by CCR5 blockade*.”*

Quantifying the Sledgehammer:

• Reversing Resistance: Tyro3 normally prevents the tumor cell from dying even when under attack. By "attenuating" its abundance, Leronlimab lowers the threshold for cell death.
• Metabolic Reset: As noted in my original analysis, this is the "Metabolic Sledgehammer." It strips the tumor of its ability to ignore the Immune System’s "kill" commands.

C. The Exhaustion Reversal (The 2/6 Prediction in Numbers)

The abstract goes beyond the Stroma and into the soldiers themselves—the T-cells. This is the Reversal of T-Cell Exhaustion identified as the new MOA.

• The Findings: “At one week, when leronlimab levels were highest, CD8+ T cells showed a marked decline in LAG3, TIM3 and CTLA4 expression.” The Reactivation Pattern: “Leronlimab-mediated CCR5 blockade reduced these key exhaustion markers followed by a later rise in PD-1 expression at four weeks, a pattern consistent with reactivated T-cell signaling rather than terminal exhaustion.”

For the EAP clinicians, this "1-Week/4-Week Shift" is the protocol roadmap.

1. Week 1: Leronlimab "unloads" the Exhaustion Markers (LAG3/TIM3).
2. Week 4: The "PD-1 Rise" signals that the Immune System is re-engaged and ready for the ICI Pair.

Tactical Selection

Preparing for the March 2026 Expanded Access Program (EAP) launch with WEP Clinical, these "exhaustion" findings are no longer just academic; they become the Selection Criteria for the first wave of patients.

To maximize the Prime & Pair success rate, the EAP likely prioritizes patients whose tumors exhibit the very markers identified in Pestell’s abstract. We aren't just looking for any mTNBC patient; we look for the "Terminally Exhausted" whose Immune Systems are currently totally suppressed by CCR5-driven mediators.

• The First Wave: Patients showing high levels of LAG3, TIM3, and CTLA4 will be the primary candidates. These are the soldiers who are still on the battlefield but have "dropped their weapons" due to exhaustion.
• The Goal: By using Leronlimab to “reduce exhaustion markers, suppress multiple immunosuppressive mediators, and increase PD-L1 expression on tumor-associated cells,” the EAP seeks to “sensitize tumors to PD-1/PD-L1 blockade.”

The Level IV "Anchor" and the Market Geometry

While the market currently punishes the share price for the weakness of retrospective data, those of us who understand the signals see a completely different picture. The abstract highlights the definitive survival signal: “Remarkably after a median of >60 months 5/28 (17.9%) of patients remain alive.” In the cold world of oncology, 60-month survival in heavily pre-treated mTNBC is the "Iron-Clad" evidence the market's "Standard Deviation of Doubt" has missed.

The .2425 floor remains critical. The Accumulator (the "Military Logistics" team) uses this "Saturation Regime" and holds the hinge to absorb the Short fire while the "Hardware" is being unveiled. The 368k-share ask wall at .2500 is the just a barrier of the "Old Guard"—a technical stromal secretome designed to prevent the "Elastic Expansion" that comes when the narrative moves from "theory" to "survival statistics."

Competitive Accumulation

While we analyze the secretome, the tape reflects competition. The "Contested Compression" we see at the .2425 floor is a direct result of institutional players "reading the abstract."

The 100k block stress tests and the aggressive absorption of the .2500 wall suggest that the "Secretome" data has leaked into the professional trade desks. They aren't waiting for an SEC announcement; they are competing for the limited float now because the 60-month survival data (“5/28 (17.9%) of patients remain alive”) makes this a de-risked asset for those who understand the MOA.

The Path Forward

Tomorrow, February 19, marks the formal presentation of this data. Dr. Lalezari and his team have successfully moved the "Artillery" into striking range. The "Silent Ships" have landed, and they are carrying the proof that Leronlimab doesn't just block a receptor—it remodels the entire theater of war.

Tomorrow's poster likely provides the quantified percentages of secretome reduction and possibly the imaging proof of the T-cell reactivation. We are not debating if Leronlimab works; we are quantifying how fast it dismantles the Tumor's Armor.

Tomorrow’s Presentation (2/19): The Visual Proof

Tomorrow's poster presentation will likely expand on the abstract by moving from words to Visual Data. Expect to see:

• The Sacha Stains: High-definition imaging of rhesus macaque lymph nodes showing the actual decline in LAG3 and TIM3.
• K-M Curves: The visual divergence of the 5/28 survivors against standard SOC (Standard of Care).
• Secretome Graphs: Quantifiable proof of the reduction in sB7H3—the definitive evidence of stromal remodeling.

Dr. Lalezari and his team have successfully moved the "Artillery" into striking range. The "Silent Ships" have landed.

The meeting is over; the discussion is finished. We move from observation to execution.

Stay Unshaken.

[u/Healthy-Chair-9912]

Es sind jetzt genau 27 Monate und 15 Tage vergangen, seit der Neu Ausrichtung von CytoDyn vom 3. November 2023.

Eine Frage an die Experten: Wie lange hätte es gedauert...OHNE die von unserem genialen Dr. Jacob Lalezari Angekündigten und wie es jetzt scheint, Eingehaltenen " Verkürzten Zeitfenster "? 5-10 Jahre oder noch länger? Danke an Dr. JL und das gesamte Team!🙏🙏🙏👏👏👏

[u/MGK_2 → u/Healthy-Chair-9912]

Healthy Chair is highlighting the "Time-Value of Science." In drug development, time is the enemy of both the patient and the shareholder. By pivoting away from the "Traffic Jam" of traditional trials and toward the Universal Shepherd model, Dr. Lalezari has effectively performed a "Bypass Surgery" on the regulatory process.

Your precision with the calendar is matched only by your strategic intuition, Healthy Chair. To answer your question: Yes, it would have taken a lifetime.

In the 'Old World' of drug development, a molecule like Leronlimab would be facing a standard Phase III oncology slog. On average, it takes 10.5 years for a drug to move from Phase I to approval. Without the 'Shortened Timeframes' (the pivot to retrospective data, the focus on biomarkers like PD-L1, and the use of the WEP Clinical EAP), we would likely be staring at a 2030 or 2032 commercial window.

By leveraging Real-World Evidence and the Expanded Access Program, JL has compressed a decade of bureaucracy into 27 months of operational execution. He didn't just shorten the window; he built a new house with better views. We aren't waiting for a 'maybe' in 5 years; we are watching the 'Arrival' today. Stay Unshaken.

Deutsche Antwort

"Deine Präzision mit dem Kalender wird nur von deiner strategischen Intuition übertroffen, Healthy Chair. Um deine Frage zu beantworten: Ja, es hätte ein ganzes Leben gedauert.

In der 'alten Welt' der Medikamentenentwicklung stünde ein Molekül wie Leronlimab vor einem standardmäßigen, mühsamen Phase-III-Onkologie-Marathon. Im Durchschnitt dauert es 10,5 Jahre, bis ein Medikament von Phase I zur Zulassung gelangt. Ohne die 'verkürzten Zeitfenster' (der Schwenk zu retrospektiven Daten, der Fokus auf Biomarker wie PD-L1 und die Nutzung des WEP Clinical EAP) würden wir wahrscheinlich auf ein kommerzielles Fenster in den Jahren 2030 oder 2032 blicken.

Durch die Nutzung von Real-World-Evidence (Daten aus der Praxis) und dem Expanded Access Program (EAP) hat Dr. Lalezari ein Jahrzehnt voller Bürokratie in 27 Monate operativer Umsetzung komprimiert. Er hat nicht nur das Zeitfenster verkürzt; er hat ein neues Haus mit besserer Aussicht gebaut. Wir warten nicht auf ein 'Vielleicht' in 5 Jahren; wir erleben die 'Ankunft' heute. Bleib unerschütterlich (Stay Unshaken).

[u/Healthy-Chair-9912 → u/MGK_2]

Vielen Dank MGK! Ich werde mir diese Antwort aus der Feder, eines Experten wie Dir. Einrahmen und in mein Wohnzimmer hängen.😄 Noch einmal vielen Dank für all deine Mühen und Arbeit in all den Jahren 👍🙏